History
As We are taking a powerful step toward the establishment of a century.
“The path JW Pharmaceutical which is the company founded at Independent year has come”
“The path JW Pharmaceutical which is the company founded at Independent year has come”
2019
- ∙ C&C Research Laboratories, JW Pharmaceutical Subsidiary transfer
- ∙ Signed a technology export contract with the Simcere company in China,'URC102' for gout treatment
- ∙ Acquired 'Euvipharm', the first Vietnamese pharmaceutical company in Korea
- ∙ Atopic dermatitis ‘JW1601’ won the ‘Technology Exporter’ and the 'King Sejong the Great', the highest patented technology in Korea
- ∙ Atopic dermatitis drugs 'JW1601' US FDA approved clinical
- ∙ A hemophilia drug 'hemri Bra' rare drug designation and market sales permit
- ∙ Rivaro E tablet (Pitavastatin / Ezetinib combination) Phase 1 clinical trial success
- ∙ Asia’s first sell a three-chamber nutrient infusion in EU
2018
- ∙ JW Life Science Industry First ‘Nutrient Toolking’ in Asis get EU-GMP
- ∙ Technology export of atopic dermatitis drug 'JW1601'
2017
- ∙ Government Award for Excellent Innovative Pharmaceutical
Company (by the Minister of Health and Welfare) - ∙ Ensured prior-sales right and avoided dorifenem's patent of
penem anti-biotic <Pinipenem> successfully - ∙ Completed clinical demonstration 2 of gout remedy
(URC-102) and announced the results (American College of
Rheumatology, ACR) - ∙ Announced the clinical design of multiple myeloma of Wnt
target anti-cancer drug (CW291) (American Society of
Clinical Oncology, ASCO) - ∙ Conducted the stomach cancer clinical demonstration of
Wnt target anti-cancer drug <CWP291> (Researcher-led
clinical demonstration) clinical demonstration 1 - ∙ Concluded an agreement for non-clinical trial research with
the new drug development project division of the Ministry
of Health and Welfare for atopic dermatitis treatment
(FR-1345) - ∙ Owned the sales rights in Korea for anemia treatment
<JTZ-951> - ∙ Owned the sales rights in Korea for hemophilia A treatment
<ACE910> production facility
2016
- ∙ Announced Wnt target anti-cancer drug <CWP291>
acute myeloid leukemia clinical demonstration phase 1 clinical results - ∙ Approved Wnt target anti-cancer drug <CWP291>
acute myeloid leukemia clinical demonstration 1b by Korean and the US IND - ∙ Announced Wnt target anti-cancer drug <CWP291> multiple myeloma clinical demonstration 1a, b intermediate results (American Society of Hematology, ASH)
- ∙ Completed gout treatment <URC-102> clinical demonstration 2
2015
- ∙ Vision 70+5 Declaration
2013
- ∙ Signed Export Agreement with America’s Baxter for
3-Chamber Nourishment Transfusion Fluid - ∙ Joint-Development agreement with Japan’s SKK worth 100
billion for pharmaceutical products
2012
- ∙ Relocation of C&C new drug research Institute
(DRC center, Natural Science Campus,
Sungkyunkwan University inSuwon) - ∙ Relocation of headquarters
(2477 Nambusunhwan Ro- Seocho-dong, Seocho-gu, Seoul
2011
- ∙ Change in Group CI and Company name
(JW Pharmaceutical Co.,Ltd.) - ∙ We enter the clinical phase for what target anti-cancer\
drug in the United States - ∙ We develop Zepeed Erectile dysfunction, avanafil,
which is a domestic 17th new drug
2010
- ∙ Completion of construction of JW Dangjin production
complex which is the nation’s largest production
2008
- ∙ Selected as ‘excellent company with Harmonization
between Management and Labors by Ministry of Labor
2007
- ∙ Recipient of the presidential medal on the 12th day of environment Launching of JW holdings
- ∙ Selected as a ‘bio-Star’ In the project for support of
the development of drug discovery by Ministry of Commerce, Industry and Energy. - ∙ Citizens’ Coalition for Economic Justice, we are ranked the first among Pharmaceutical companies in the field of economic justice/ We are ranked at least 8th in all sectors
2006
- ∙ Construction of a plant specialized for Non PVC iv
solution in the world’s largest amount
(Chungnam DangJin).
2005
- ∙ Development of therapeutic agent for colon cancer with new concept as the world’s first (identification of drug which blocks CBP-beta catenin binding)
- ∙ Selected as ’30 Korean companies which are respected in 2005’ (Donga Ilbo and IBM BCS)
- ∙ Selected as ‘the best Asian 200 companies’ (Frbes Asia)
- ∙ Merger of Daeyoo Pharmaceutical Co.,Ltd. And JW Medical CO., Ltd. And establishment of JW Shinyak Co.,Ltd.
2004
- ∙ Success in development of antibiotic ‘imipenem’ with a
mega size of 0.6 billion dollars for the first time)
2003
- ∙ Recipient of the 3rd Gyeonggi environment green grand (Gyeonggi Province)
- ∙ Recipient of the 4th Kroea corporate image grand prize (Korea Management Associationn)
- ∙ Recipient of the grand prize in the sector of corporate in 5th Gyeonggi Province Industrial Peace award
(Gyeonggi Province)
2002
- ∙ Q-rozin tab, winning an exellent award for the drug
discovery development (Korean Drug Research
Association)
2001
- ∙ Recipient of the 1st CEO grand award (Korean Professional Managers Assoiation)
- ∙ Q-roxiin tab, acquistition of approval from KFDA for a new drug in phase 3 which is the first time in Korea
2000
- ∙ Recipient of $10 million export tower Establishment of
CGEN Research - ∙ Corporation
(Contract with PNRI, USA for Collaborative study)
1999
- ∙ Recipient of the 5th Annual Grand Founder Prize
(The Korean Academy of Business Historians) - ∙ Record Production of 1billion bottles of iv solution
- ∙ Establishment of an affiliate company
: Choongwae information technology (CIT)
1998
- ∙ Development of Anti-fungal agent, Itraconazole
- ∙ Selected as the 1st most reputable domestic company
(BOSA)
1997
- ∙ Recipient of ‘4th Annual Economic Justice Award’
- ∙ Recipient of ‘Bronze Tower Industrial Medal of Honor’
- ∙ Designated as a Model Company for Harmonization
between Management and Labors (Ministry of Labor)
1995
- ∙ Establishment of an affiliate company
: Choongwae Chemical Co.,Ltd. - ∙ Development of Anti-arrhythmia agent, KCB new agent
1994
- ∙ Deignated as an ‘Exemplary Environment Management
Corporation’ by the govemment for three consecutiive years
1993
- ∙ Merger of Choongwae Machinery Co.,Ltd. And Choongwae
Commercial Co.,Ltd. : Choongwae Medical co.,Ltd was
launched.
1992
- ∙ Establishment of C&C new drug research Institute
1991
- ∙ Name Change : From Jungmo Pharmaceutical Co.,Ltd.
To Daeyoo Pharmaceutical Co.,Ltd. - ∙ Designated as a company for all dosage forms to cmply
with KGMP (Ministry of Health and Welfare)
1990
- ∙ Acquisition of company : Jungmo Pharmaceutical Co.,Ltd
- ∙ Recipient of ‘National Medal of Honor, Moran’
1988
- ∙ Establishment of an affiliate company
: Choongwae industrail Co.,Ltd.
1987
- ∙ Construction of Yongin Plant of
Choongwae Commercial Corporation - ∙ Designated as a company to comply with KGMP
(Ministry of Health and Welfare) - ∙ Recipient of ‘National Medal of Honor, MokRyun’
1986
- ∙ Construction and relocation of Headquarters building
: 698 Shindaebang-dong, Donjak-Gu, Seoul.
1984
- ∙ Recipient of ‘Saemaeul Medal of Honor for cooperation’
1983
- ∙ Establishment of Choongwae Research Institute
: Designated as a private affiliated laboratory of Ministry
of Science Technology.
1982
- ∙ Change of Corporation Name :
Choongwae Pharmaceutical CO.,Ltd
1977
- ∙ Construction and relocation of an new plant
: 146-141, Annyung-ri, Taene-eup, Hwasung-gun,
Gyeonggi Province - ∙ Establishment of an affilate company :
Choongwae Machinery Co.,Ltd
1976
- ∙ Initial Public Offering (Invitation of public to new stocks) :
88 milion won in the Capital
– listed on the Korea Stock Exchange Market.
1975
- ∙ Setting up the manufacturing records and batch test records
based onJGMP standards (First in Korea)
1972
- ∙ Establishment of an affiliate company
: Daehan Choongwae Commercial Co.,Ltd.
1969
- ∙ Recipient of inventor’s award
: Development of TC soluble derivative method
(Lymecycline HCL)
1953
- ∙ Establishment of corporation
: Daehan Choongwae Pharmaceutical Co.,Ltd.
1945
- ∙ Establishment of company : Choongwae Pharmaceutical
(Choongmu-ro 3 Ga, Choong-gu, Seoul)